NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols
暂无分享,去创建一个
E. Petricoin | W. Kamps | R. Pieters | E. Petricoin | A. Veerman | J. Meijerink | M. Horstmann | E. Sonneveld | J. Buijs-gladdines | V. Calvert | I. Homminga | L. Zuurbier | W. Smits | C. Kooi | M. L. Winkel | M. T. Winkel | J. Buijs-Gladdines | Willem K. Smits | M. L. T. Winkel
[1] R. Pieters,et al. Biology and treatment of acute lymphoblastic leukemia. , 2010, Hematology/oncology clinics of North America.
[2] M. Muckenthaler,et al. The Favorable Effect of Activating NOTCH1 Receptor Mutations On Long Term Outcome in T-ALL Is Treatment Related and Can Be Separated From NOTCH Pathway Activation by FBXW7 Loss of Function. , 2009 .
[3] F. Speleman,et al. Prognostic Significance of NOTCH1 and FBXW7 Mutations in Childhood T-Cell Acute Lymphoblastic Leukemia (T-ALL): Results From the EORTC Children Leukemia Group. , 2009 .
[4] W. Kamps,et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). , 2009, The Lancet. Oncology.
[5] C. Bloomfield,et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia , 2009, Haematologica.
[6] A. Ferrando,et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Iannis Aifantis,et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia , 2009, Nature.
[8] H. Dombret,et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. , 2009, Blood.
[9] Y. Hayashi,et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non‐Hodgkin lymphoma , 2009, British journal of haematology.
[10] A. Gedman,et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T- cell acute lymphoblastic leukemia: A report from the Children's Oncology Group , 2009, Leukemia.
[11] Robin Foà,et al. T-cell acute lymphoblastic leukemia , 2009, Haematologica.
[12] Shinsuke Suzuki,et al. A second NOTCH1 chromosome rearrangement: t(9;14)(q34.3;q11.2) in T-cell neoplasia , 2009, Leukemia.
[13] J. Aster,et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. , 2008, Blood.
[14] R. Pieters,et al. Molecular‐genetic insights in paediatric T‐cell acute lymphoblastic leukaemia , 2008, British journal of haematology.
[15] J. Aster,et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. , 2008, The Journal of clinical investigation.
[16] A. Ferrando,et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. , 2008, Blood.
[17] L. Foroni,et al. Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia , 2007, Clinical Cancer Research.
[18] Andrew P. Stubbs,et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. , 2007, Blood.
[19] Rob Pieters,et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors , 2007, The Journal of experimental medicine.
[20] A. Ferrando,et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia , 2007, The Journal of experimental medicine.
[21] U. Lendahl,et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. , 2007, Cancer research.
[22] Gabriel S. Eichler,et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. , 2007, Cancer research.
[23] Adam A. Margolin,et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth , 2006, Proceedings of the National Academy of Sciences.
[24] Charles Lee,et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. , 2006, Blood.
[25] H. J. Kim,et al. Mutational analysis of the hCDC4 gene in gastric carcinomas. , 2006, European journal of cancer.
[26] M. Muckenthaler,et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. , 2006, Blood.
[27] J. Aster,et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.
[28] Jiong Hu,et al. NOTCH1 Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis , 2006, Clinical Cancer Research.
[29] A. Look,et al. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia , 2006, Nature Reviews Cancer.
[30] Andrew P. Weng,et al. Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.
[31] F. Speleman,et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. , 2004, Blood.
[32] E. Macintyre,et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRγδ lineage , 2003 .
[33] S. Armstrong,et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. , 2003, Blood.
[34] E. Petricoin,et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.
[35] C. Li,et al. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] W. Kamps,et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). , 1999, Blood.
[37] A Orfao,et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.
[38] J. Sklar,et al. TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms , 1991, Cell.
[39] Y. Benjamini,et al. More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.
[40] M. D. Den Boer,et al. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. , 2009, Seminars in hematology.
[41] Iannis Aifantis,et al. γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia , 2009, Nature Medicine.
[42] J. Meijerink,et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences , 2008, Leukemia.
[43] M. Eguchi,et al. NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. , 2008, Blood.
[44] W. Kamps,et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. , 2006, Haematologica.
[45] E. Macintyre,et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. , 2003, Blood.
[46] J. Hermans,et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996) , 2002, Leukemia.
[47] G. Paolucci,et al. [Treatment of acute lymphoblastic leukemia]. , 1971, Minerva pediatrica.